Andrew Acheson, co-manager of the €1.4bn Pioneer SICAV - US Fundamental Growth fund, said he defended himself against August's biotech sell-off by holding established stocks with room for growth rather than "paying for the hope of the future".
The manager said the fund outperformed its Russell 1000 Growth benchmark over the last three months, despite being overweight the wider healthcare sector during a period when the NASDAQ Biotechnology index...
Latest edition of the print magazine online
Latest news and analysis
Industry Voice: How should bond investors approach markets such as Turkey and Argentina?
MSCI and Hermes research
Burton Malkiel: I believe in indexing even more strongly now than when I wrote 'A Random Walk Down Wall Street'
Best approach even in inefficient markets